3Lamouliatte H, Cayla R, Zerbib F, et al. Essai controle randomise comparant la bitherapie (Lansorazole a dose amoxicilline) a la tritherapie (Lansorazole a forte dose amoxycilline - clarithromycine) dans L'infection a Helicobacter pylori. Gastroenterol Chin Biol 1995;19(2):189.
3LABENZ J, PETERSEN K U, ROSCH W, et al. A summary of Food and Drug Administration-reported adverse events and drug interactions occurring during therapy with omeprazole, lansoprazole and pantoprazole [ J]. Aliment Pharmacol Ther,2003,17 (8) : 1015-1019.
4MIURA M. Enantioseleetive disposition of lansoprazole and rabeprazole in human plasma[ J ]. Yakugaku Zasshi,2006, 126(6) :395-402.
5KIM K A, KIM M J, PARK J Y, et al. Stereoselective me-tabolism of lansoprazole by human liver cytochrome P450 enzymes[J]. Drug Metab Dispos, 2003,31 (10) :1227- 1234.
6ISHIZAKI T, HORAI Y. Review article: eytochrome P450 and the metabolism of proton pump inhibitors emphasis on rabeprazole [ J]. Aliment Pharmacol Ther, 1999, 13 ( Suppl 3) :27-36.
7MIURA M, KAGAYA H, TADA H, et al. Intestinal CYP3A4 is not involved in the enantioselective disposition of lansoprazole [ J ]. Xenobiotica, 2006,36 ( 1 ) : 95-102.
8TRAN A, REY E, PONS G, et al. Pharmacokinetic-pharmacodynamic study of oral lansoprazole in children [ J ]. Clin Pharmacol Ther,2002,71 (5) :359-367.
9CROOM K F, SCOTT L J. Lansoprazole: in the treatment of gastro-oesophageal reflux disease in children and adolescents[ J]. Drugs ,2005,65 ( 15 ) :2129-2135.
10GREMSE D, WINTER H, TOLIA V, et al. Pharmacokinetics and pharmacodynamics of lansoprazole in children with gastroesophageal reflux disease[ J ]. J Pediatr Gastroenterol Nutr, 2002,35 ( Suppl 4 ) : 319-326.
